Complex Oncological Center - Plovdiv, EOOD

Futó vizsgálatok

• Toboroz

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· 3. fázis· Forrás

• Toboroz

  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  NCT06982521· 3. fázis· Forrás

• Toboroz

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· 3. fázis· Forrás

• Toboroz

  An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

  NCT07033026· 2. fázis· Forrás

• Toboroz

  Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  NCT06819007· 3. fázis· Forrás

• Fut, nem toboroz

  Phase 2/3 Randomized Study of INBRX-106 Add-on to Pembrolizumab in First-Line PD-L1 CPS ≥20 R/M HNSCC (HexAgon-HN)

  2024-515538-34-00· 2/3. fázis· Forrás

• Toboroz

  Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

  NCT06712316· 2/3. fázis· Forrás

• Fut, nem toboroz

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· 3. fázis· Forrás

• Toboroz

  A clinical study on SHR3680 combined with androgen deprived therapy (ADT) versus Bicalutamide combined with ADT in treatment of prostate cancer

  NCT03520478· 3. fázis· Forrás

• Fut, nem toboroz

  Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

  NCT06635824· 3. fázis· Forrás

• Toboroz

  A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

  NCT06629779· 3. fázis· Forrás

• Toboroz

  A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  NCT06452277· 3. fázis· Forrás

• Toboroz

  Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

  NCT06380751· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

  NCT06459180· 3. fázis· Forrás

• Toboroz

  A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  NCT06345729· 3. fázis· Forrás

• Fut, nem toboroz

  Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

  NCT06117774· 3. fázis· Forrás

• Fut, nem toboroz

  Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

  NCT05874401· 4. fázis· Forrás

• Fut, nem toboroz

  ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study

  NCT05596409· 2. fázis· Forrás

• Fut, nem toboroz

  Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

  NCT05678673· 3. fázis· Forrás

• Toboroz

  A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

  NCT04928846· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

  NCT05239728· 3. fázis· Forrás

• Fut, nem toboroz

  Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.

  NCT05038735· 3. fázis· Forrás

• Fut, nem toboroz

  A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 mutation

  NCT04964934· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

  NCT04821622· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

  NCT04770896· 3. fázis· Forrás

• Fut, nem toboroz

  Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

  NCT04700124· 3. fázis· Forrás

• Fut, nem toboroz

  A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

  NCT04711252· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

  NCT04607421· 3. fázis· Forrás

• Toboroz

  Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  NCT04613596· 2/3. fázis· Forrás

• Fut, nem toboroz

  A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

  NCT04497844· 3. fázis· Forrás

• Fut, nem toboroz

  PF-07104091 as a Single Agent and in Combination Therapy

  NCT04553133· 2. fázis· Forrás

• Fut, nem toboroz

  Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

  NCT04421963· 3. fázis· Forrás

• Fut, nem toboroz

  Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

  NCT04493853· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Áttétes emlőrák4 toboroz
• Tüdőrák4 toboroz
• Petefészekrák2 toboroz
• Prosztatarák2 toboroz
• Hasnyálmirigyrák1 toboroz
• Szarkóma1 toboroz
• Vastagbélrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Fut, nem toboroz

  Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

  NCT06211036· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

  NCT06105632· 2. fázis· Forrás

• Lezárult

  A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT05848011· 2. fázis· Forrás

• Fut, nem toboroz

  A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

  NCT05654623· 3. fázis· Forrás

• Toboroz

  Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

  NCT04953910· 1. fázis· Forrás

• Lezárult

  A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

  NCT05415215· 3. fázis· Forrás

• Toboroz

  Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

  NCT04953897· 1. fázis· Forrás

• Lezárult

  A Study of Atezolizumab with Lenvatinib or Sorafenib versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated with Atezolizumab and Bevacizumab

  2023-503229-21-00· 3. fázis· Forrás

• Meghívásos bevonás

  A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

  NCT04093570· 2. fázis· Forrás

• Lezárult

  Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC

  NCT03834493· 3. fázis· Forrás

• Lezárult

  A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

  NCT03782207· Forrás

• Fut, nem toboroz

  Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

  NCT03737643· 3. fázis· Forrás

• Toboroz

  A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

  NCT03460977· 1. fázis· Forrás

• Lezárult

  A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)

  NCT02913456· Forrás